In the present study, we examined the effects of pharmacologic inhibition of myostatin with a myostatin‐blocking antibody (REGN647(27, 28)) in the skeletal muscle and bone properties of an animal model of insulin‐deficient (T1D) diabetes, with and without insulin treatment. Here, INS is linked to type 1 diabetes mellitus.